Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-17 EDT			5-day change	1st Jan Change
488.4 ^USD	-0.12%		-0.66%	+20.03%

07-16	Vertex Pharmaceuticals, Genomics Extend Drug Discovery, Development Collaboration by 3 Years	MT
07-16	Genomics plc Announces New Extension and Expansion of Drug Discovery Collaboration with Vertex Pharmaceuticals Incorporated	CI

Vertex Pharmaceuticals Incorporated Provides Revenue Guidance for the Full Year of 2015

January 12, 2015 at 12:30 pm

Vertex Pharmaceuticals Incorporated provided revenue guidance for the full year of 2015. In 2015, the company expects significant revenue growth, the expansion of KALYDECO. Again the company is giving guidance of $560 million to $580 million, a 20% to 25% increase over the $460 million that the company expects to record this year.

Latest news about Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals, Genomics Extend Drug Discovery, Development Collaboration by 3 Years	07-16	MT
Genomics plc Announces New Extension and Expansion of Drug Discovery Collaboration with Vertex Pharmaceuticals Incorporated	07-16	CI
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $589 From $577, Maintains Buy Rating	07-16	MT
Vertex Sues U.S. to Pay for Fertility Treatments	07-15	DJ
Vertex Files Lawsuit Against US Government to Pay for Fertility Treatment for Patients	07-15	MT
Vertex sues US over fertility support program for Casgevy gene editing therapy	07-15	RE
Vertex Pharmaceuticals Gets Health Canada Approval for Expanded Trikafta Use in Cystic Fibrosis Treatment	07-15	MT
Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for Trikafa® for People with Cystic Fibrosis Aged 2 Years and Older with Certain Rare Mutations	07-15	CI
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $455 From $402	07-11	MT
RBC Raises Price Target on Vertex Pharmaceuticals to $431 From $421, Keeps Sector Perform Rating	07-09	MT
FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	07-02	MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	07-02	DJ
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	CI
Verve Therapeutics, Inc. Announces Board and Committee Appointments	06-28	CI
Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target	06-27	MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating	06-25	MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540	06-24	MT
Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes	06-21	MT
Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes	06-21	CI
Vertex Pharmaceuticals Has Pricing Accord for Cystic Fibrosis Drugs With UK National Health Service	06-20	MT
Argus Adjusts Price Target on Vertex Pharmaceuticals to $550 From $465	06-17	MT
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials	06-14	MT
Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on CASGEVY (Exagamglogene Autotemcel)	06-14	CI
Vertex Pharmaceuticals Insider Sold Shares Worth $1,089,840, According to a Recent SEC Filing	06-13	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,483,664, According to a Recent SEC Filing	06-13	MT

Chart Vertex Pharmaceuticals Incorporated

Duration

Period

Chart Vertex Pharmaceuticals Incorporated

More charts

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

Biotechnology & Medical Research

Calendar

2024-08-01 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

488.4 USD

Average target price

473.5 USD

Spread / Average Target

-3.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	117B
ARGENX SE	+22.91%	27.52B
BIONTECH SE	-18.07%	20.87B
GENMAB A/S	-14.01%	17.01B
BEIGENE, LTD.	-14.81%	16.26B
WUXI APPTEC CO., LTD.	-46.10%	15.09B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.56B
SAREPTA THERAPEUTICS, INC.	+52.34%	13.89B
INSMED INCORPORATED	+143.76%	12.18B

Bio Therapeutic Drugs